Division of Transplant Nephrology, University of California San Francisco, San Francisco, CA.
Division of Transplant Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN.
Transplantation. 2024 Aug 1;108(8):1782-1792. doi: 10.1097/TP.0000000000004985. Epub 2024 Jul 20.
Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease and frequently recurs after kidney transplantation. Recurrent FSGS (rFSGS) is associated with poor allograft and patient outcomes. Bleselumab, a fully human immunoglobulin G4 anti-CD40 antagonistic monoclonal antibody, disrupts CD40-related processes in FSGS, potentially preventing rFSGS.
A phase 2a, randomized, multicenter, open-label study of adult recipients (aged ≥18 y) of a living or deceased donor kidney transplant with a history of biopsy-proven primary FSGS. The study assessed the efficacy of bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression in the prevention of rFSGS >12 mo posttransplantation, versus standard of care (SOC) comprising tacrolimus, mycophenolate mofetil, and corticosteroids. All patients received basiliximab induction. The primary endpoint was rFSGS, defined as proteinuria (protein-creatinine ratio ≥3.0 g/g) with death, graft loss, or loss to follow-up imputed as rFSGS, through 3 mo posttransplant.
Sixty-three patients were followed for 12 mo posttransplantation. Relative decrease in rFSGS occurrence through 3 mo with bleselumab versus SOC was 40.7% (95% confidence interval, -89.8 to 26.8; P = 0.37; absolute decrease 12.7% [95% confidence interval, -34.5 to 9.0]). Central-blinded biopsy review found relative (absolute) decreases in rFSGS of 10.9% (3.9%), 17.0% (6.2%), and 20.5% (7.5%) at 3, 6, and 12 mo posttransplant, respectively; these differences were not statistically significant. Adverse events were similar for both treatments. No deaths occurred during the study.
In at-risk kidney transplant recipients, bleselumab numerically reduced proteinuria occurrence versus SOC, but no notable difference in occurrence of biopsy-proven rFSGS was observed.
局灶节段性肾小球硬化症(FSGS)是终末期肾病的常见病因,肾移植后常复发。复发性 FSGS(rFSGS)与移植物和患者预后不良相关。Bleselumab 是一种完全人源 IgG4 抗 CD40 拮抗单克隆抗体,可破坏 FSGS 中的 CD40 相关过程,从而可能预防 rFSGS。
这是一项针对成人接受活体或已故供体肾移植的 2a 期、随机、多中心、开放标签研究,这些患者有活检证实的原发性 FSGS 病史。该研究评估了 bleselumab 联合他克莫司和皮质类固醇作为维持免疫抑制治疗在预防移植后 12 个月以上 rFSGS 方面的疗效,与包括他克莫司、霉酚酸酯和皮质类固醇的标准治疗(SOC)相比。所有患者均接受巴利昔单抗诱导。主要终点是 rFSGS,定义为蛋白尿(蛋白尿-肌酐比≥3.0 g/g)伴死亡、移植物丢失或失访,通过移植后 3 个月推断为 rFSGS。
63 例患者在移植后 12 个月时进行了随访。与 SOC 相比,bleselumab 组在 3 个月时 rFSGS 发生率的相对下降为 40.7%(95%置信区间,-89.8 至 26.8;P=0.37;绝对下降 12.7%[95%置信区间,-34.5 至 9.0])。中心盲法活检评估发现,rFSGS 在移植后 3、6 和 12 个月时的相对(绝对)下降分别为 10.9%(3.9%)、17.0%(6.2%)和 20.5%(7.5%);这些差异无统计学意义。两种治疗的不良反应相似。研究期间无死亡发生。
在高危肾移植受者中,bleselumab 与 SOC 相比可减少蛋白尿的发生,但在活检证实的 rFSGS 发生率方面未观察到显著差异。